05.05.2022 15:09:02
|
Myriad Genetics Inc. Q1 Loss Increases, but beats estimates
(RTTNews) - Myriad Genetics Inc. (MYGN) released Loss for first quarter that decreased from the same period last year but missed the Street estimates.
The company's bottom line came in at -$20.5 million, or -$0.26 per share. This compares with -$39.5 million, or -$0.52 per share, in last year's first quarter.
Excluding items, Myriad Genetics Inc. reported adjusted earnings of -$2.8 million or -$0.03 per share for the period.
Analysts on average had expected the company to earn -$0.07 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 4.7% to $164.9 million from $173.1 million last year.
Myriad Genetics Inc. earnings at a glance (GAAP) :
-Earnings (Q1): -$20.5 Mln. vs. -$39.5 Mln. last year. -EPS (Q1): -$0.26 vs. -$0.52 last year. -Analyst Estimates: -$0.07 -Revenue (Q1): $164.9 Mln vs. $173.1 Mln last year.
-Guidance: Full year EPS guidance: Adj: $0.00 - $0.20 Full year revenue guidance: $670 - $700 Mln
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Myriad Genetics Inc.mehr Nachrichten
Analysen zu Myriad Genetics Inc.mehr Analysen
Aktien in diesem Artikel
Myriad Genetics Inc. | 14,50 | 3,57% |